期刊文献+

新疆乌鲁木齐市2014年HIV-1耐药毒株传播分析 被引量:2

Survey on transmitted HIV-1 drug resistance in Urumqi,Xinjiang in 2014
原文传递
导出
摘要 目的 调查乌鲁木齐市2014年艾滋病病毒1型(HIV-1)耐药毒株的传播情况。方法 参考世界卫生组织(WHO)的艾滋病传播性耐药调查方法,按确证时间顺序采集当年16~25岁新确证HIV-1感染者全血样本33份,分离血浆,提取病毒基因组RNA,扩增包含完整蛋白酶编码区和反转录酶1~250氨基酸基因区的pol基因片段并测序,利用Mega 6.0软件,通过与参考株pol序列构建进化树确定HIV-1亚型,pol序列与Stanford耐药数据库中的共享序列进行比对,利用WHO提供的CPR 5.0软件分析传播性耐药突变位点和耐药程度。结果 检测的33份样本中成功获得序列的有32份,亚型以CRF07-BC(50.0%,16/32)为主,其次是CRF01-AE(34.4%,11/32)。32份样本中只有1份出现了耐药传播相关的突变位点,耐药传播率为3.1%(1/32)。结论乌鲁木齐市2014年的耐药传播水平较低,但应继续定期进行HIV-1耐药毒株传播的监测,了解HIV-1耐药毒株传播的动态变化。 Objective To evaluate the level of transmitted human immunodeficiency virus (HIV) drug resistance in Urumqi in 2014. Methods Following the WHO protocols for surveillance of transmitted HIV drug resistance (HIVDR), blood specimens were consecutively collected from 33 newly diagnosed HIV-1 infected individuals be- tween 16 and 25 years old. Plasma was separated from the whole blood. Then viral RNA was extracted from plasma specimens. A Pol fragment containing the whole protease open reading frame and 1 to 250 amino acid of reverse transcriptase gene was amplified and sequenced. HIV-1 subtypes were determined by constructing phylogenetic trees with the obtained and reference pol sequences using Mega 6.0. The pol sequences were aligned and compared with the consensus pol sequence in Stanford HIVdb. The transmitted drug resistance mutations were identified using CPR 5.0 provided by WHO, and the levels of drug resistance was determined accordingly. Results 32 specimens were successfully amplified and sequenced. Among them, 50.0 % (16/32) were CRF07_BC, follow by CRF01_AE (34.4%, 11/32). Only one of the 32 genotyped specimens were identified to have a mutation associated with drug resistance (K103N) in the reverse transcriptase gene, which could lead to a high level of drug resistances to both EFV and NVP. Conclusion The prevalence of transmitted HIVDR is relatively low in Urumqi. To provide more solid data for the prevention and care of HIV/AIDS, surveillance of transmitted HIVDR should be periodically per-formed,
出处 《中国艾滋病性病》 CAS 北大核心 2016年第8期586-588,共3页 Chinese Journal of Aids & STD
基金 国家"十二五"科技重大专项"我国HIV主要毒株的流行趋势 基因变异 耐药逃逸和评估预测研究"(2012ZX1001-002)~~
关键词 艾滋病病毒1型 耐药性检测 抗反转录病毒治疗 传播性耐药 HIV-1 Drug resistance genotyping Antiretroviral therapy Surveillance of transmitteddrug resistance
  • 相关文献

参考文献6

二级参考文献69

  • 1潘启超,薛以乐,康来仪,钟平,郑晓虹,林庆能,潘孝彰,金子辰,张玮,沈方伟,方蕙,宁镇,陈安琪,徐明珠,高咸明,庄鸣华,袁政安.上海市艾滋病感染者和病人中蛋白酶抑制剂耐药基因型的研究[J].上海预防医学,2004,16(7):311-313. 被引量:8
  • 2何卫华,周沛林,何华仙,张杨,黄希平,吴晓云,张绍兰.艾滋病病毒耐药性及其影响因素的研究[J].疾病控制杂志,2006,10(3):259-261. 被引量:8
  • 3薛以乐,宫菊丽,郑晓虹,盖晶,张玮,宁镇,庄鸣华,潘启超,卢伟,钟平,康来仪.上海市常住人口HIV-1感染者基因亚型和耐药性突变横断面研究[J].诊断学理论与实践,2007,6(3):203-209. 被引量:27
  • 4HIV-drugs-2007.Http://www.nature.com/reviews/drugdisc.
  • 5Meyer PR,Matsuura SE,Mian AM,et al.A mechanism of AZT resistance:an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase[J].Mol Cell,1999,4(1):35-43.
  • 6Balzarini J.Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy[J].Biochem Pharm,1999,58(1):1-27.
  • 7Rhee S,Fessel W,Zolopa A,et al.HIV-1 protease and reverse-transcriptase mutations:correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance[J].J Infect Dis,2005,192(3):456-465.
  • 8Parkin N,Gupta S,Chappey C,et al.The K101P and K103R/V179D mutations in HIV-1 reverse transcriptase confer resistance to NNRTI[J].Antimicrob Agents Chemother,2006,50(1):351-354.
  • 9Brown A,Precious H,Whitcomb J,et al.Reduced susceptibility of HIV-1 from patients with primary HIV infection to NNRTI is associated with variation at novel amino acid sites[J].J Virol,2000,74(22):10269-10273.
  • 10Villahermosa ML,Martinez-Irujo JJ,Cabodevilla F,et al.Synergistic inhibition of HIV-1 reverse transcriptase by combinations of chain-terminating nucleotides[J].Biochemistry,1997,36(43):13223-13231.

共引文献79

同被引文献17

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部